Cargando…

CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID

Background: Common variable immunodeficiency disorder (CVID) is one of the most frequent inborn errors of immunity, increased occurrence of malignancies, particularly lymphomas, and gastric cancers, has long been noted among CVID patients. Multifactorial etiology, including immune dysregulation, inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Kralickova, Pavlina, Milota, Tomas, Litzman, Jiri, Malkusova, Ivana, Jilek, Dalibor, Petanova, Jitka, Vydlakova, Jana, Zimulova, Alena, Fronkova, Eva, Svaton, Michael, Kanderova, Veronika, Bloomfield, Marketa, Parackova, Zuzana, Klocperk, Adam, Haviger, Jiri, Kalina, Tomas, Sediva, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349737/
https://www.ncbi.nlm.nih.gov/pubmed/30723478
http://dx.doi.org/10.3389/fimmu.2018.03135
_version_ 1783390304458506240
author Kralickova, Pavlina
Milota, Tomas
Litzman, Jiri
Malkusova, Ivana
Jilek, Dalibor
Petanova, Jitka
Vydlakova, Jana
Zimulova, Alena
Fronkova, Eva
Svaton, Michael
Kanderova, Veronika
Bloomfield, Marketa
Parackova, Zuzana
Klocperk, Adam
Haviger, Jiri
Kalina, Tomas
Sediva, Anna
author_facet Kralickova, Pavlina
Milota, Tomas
Litzman, Jiri
Malkusova, Ivana
Jilek, Dalibor
Petanova, Jitka
Vydlakova, Jana
Zimulova, Alena
Fronkova, Eva
Svaton, Michael
Kanderova, Veronika
Bloomfield, Marketa
Parackova, Zuzana
Klocperk, Adam
Haviger, Jiri
Kalina, Tomas
Sediva, Anna
author_sort Kralickova, Pavlina
collection PubMed
description Background: Common variable immunodeficiency disorder (CVID) is one of the most frequent inborn errors of immunity, increased occurrence of malignancies, particularly lymphomas, and gastric cancers, has long been noted among CVID patients. Multifactorial etiology, including immune dysregulation, infections, chronic inflammation, or genetic background, is suggested to contribute to tumor development. Here, we present the results of the first Czech nationwide study focused on epidemiology, immunology and genetic background in a cohort of CVID patients who also developed tumors Methods: The cohort consisted of 295 CVID patients followed for 3,070 patient/years. Standardized incidence ratio (SIR) was calculated to determine the risk of cancer, and Risk ratio (RR) was established to evaluate the significance of comorbidities. Moreover, immunophenotyping, including immunoglobulin levels and lymphocyte populations, was assessed. Finally, Whole exome sequencing (WES) was performed in all patients with lymphoma to investigate the genetic background. Results: Twenty-five malignancies were diagnosed in 22 patients in a cohort of 295 CVID patients. SIR was more than 6 times greater in comparison to the general population. The most common neoplasias were gastric cancers and lymphomas. History of Immune thrombocytopenic purpura (ITP) was established as a potential risk factor, with over 3 times higher risk of cancer development. The B cell count at diagnosis of lymphoma was reduced in the lymphoma group; moreover, post-treatment B and T cell lymphopenia, associated with poorer outcome, was found in a majority of the patients. Intriguingly, no NK cell depression was observed after the chemotherapy. WES revealed heterogeneous genetic background among CVID patients with tumors, identifying gene variants associated with primary immunodeficiencies (such as CTLA4, PIK3CD, PMS2) and/or increased cancer susceptibility (including BRCA1, RABEP1, EP300, KDM5A). Conclusions: The incidence of malignancy in our CVID cohort was found to be more than 6 times greater compared to the general population. Gastric cancers and lymphomas were the most frequently diagnosed tumors. ITP was identified as a risk factor for malignancy in CVID patients. WES analysis confirmed a wide genetic heterogeneity among CVID patients. The identified causative or modifying gene variants pointed to errors in mechanisms contributing to both immunodeficiency and malignancy.
format Online
Article
Text
id pubmed-6349737
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63497372019-02-05 CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID Kralickova, Pavlina Milota, Tomas Litzman, Jiri Malkusova, Ivana Jilek, Dalibor Petanova, Jitka Vydlakova, Jana Zimulova, Alena Fronkova, Eva Svaton, Michael Kanderova, Veronika Bloomfield, Marketa Parackova, Zuzana Klocperk, Adam Haviger, Jiri Kalina, Tomas Sediva, Anna Front Immunol Immunology Background: Common variable immunodeficiency disorder (CVID) is one of the most frequent inborn errors of immunity, increased occurrence of malignancies, particularly lymphomas, and gastric cancers, has long been noted among CVID patients. Multifactorial etiology, including immune dysregulation, infections, chronic inflammation, or genetic background, is suggested to contribute to tumor development. Here, we present the results of the first Czech nationwide study focused on epidemiology, immunology and genetic background in a cohort of CVID patients who also developed tumors Methods: The cohort consisted of 295 CVID patients followed for 3,070 patient/years. Standardized incidence ratio (SIR) was calculated to determine the risk of cancer, and Risk ratio (RR) was established to evaluate the significance of comorbidities. Moreover, immunophenotyping, including immunoglobulin levels and lymphocyte populations, was assessed. Finally, Whole exome sequencing (WES) was performed in all patients with lymphoma to investigate the genetic background. Results: Twenty-five malignancies were diagnosed in 22 patients in a cohort of 295 CVID patients. SIR was more than 6 times greater in comparison to the general population. The most common neoplasias were gastric cancers and lymphomas. History of Immune thrombocytopenic purpura (ITP) was established as a potential risk factor, with over 3 times higher risk of cancer development. The B cell count at diagnosis of lymphoma was reduced in the lymphoma group; moreover, post-treatment B and T cell lymphopenia, associated with poorer outcome, was found in a majority of the patients. Intriguingly, no NK cell depression was observed after the chemotherapy. WES revealed heterogeneous genetic background among CVID patients with tumors, identifying gene variants associated with primary immunodeficiencies (such as CTLA4, PIK3CD, PMS2) and/or increased cancer susceptibility (including BRCA1, RABEP1, EP300, KDM5A). Conclusions: The incidence of malignancy in our CVID cohort was found to be more than 6 times greater compared to the general population. Gastric cancers and lymphomas were the most frequently diagnosed tumors. ITP was identified as a risk factor for malignancy in CVID patients. WES analysis confirmed a wide genetic heterogeneity among CVID patients. The identified causative or modifying gene variants pointed to errors in mechanisms contributing to both immunodeficiency and malignancy. Frontiers Media S.A. 2019-01-22 /pmc/articles/PMC6349737/ /pubmed/30723478 http://dx.doi.org/10.3389/fimmu.2018.03135 Text en Copyright © 2019 Kralickova, Milota, Litzman, Malkusova, Jilek, Petanova, Vydlakova, Zimulova, Fronkova, Svaton, Kanderova, Bloomfield, Parackova, Klocperk, Haviger, Kalina and Sediva. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kralickova, Pavlina
Milota, Tomas
Litzman, Jiri
Malkusova, Ivana
Jilek, Dalibor
Petanova, Jitka
Vydlakova, Jana
Zimulova, Alena
Fronkova, Eva
Svaton, Michael
Kanderova, Veronika
Bloomfield, Marketa
Parackova, Zuzana
Klocperk, Adam
Haviger, Jiri
Kalina, Tomas
Sediva, Anna
CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID
title CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID
title_full CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID
title_fullStr CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID
title_full_unstemmed CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID
title_short CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID
title_sort cvid-associated tumors: czech nationwide study focused on epidemiology, immunology, and genetic background in a cohort of patients with cvid
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349737/
https://www.ncbi.nlm.nih.gov/pubmed/30723478
http://dx.doi.org/10.3389/fimmu.2018.03135
work_keys_str_mv AT kralickovapavlina cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT milotatomas cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT litzmanjiri cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT malkusovaivana cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT jilekdalibor cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT petanovajitka cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT vydlakovajana cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT zimulovaalena cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT fronkovaeva cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT svatonmichael cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT kanderovaveronika cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT bloomfieldmarketa cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT parackovazuzana cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT klocperkadam cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT havigerjiri cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT kalinatomas cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid
AT sedivaanna cvidassociatedtumorsczechnationwidestudyfocusedonepidemiologyimmunologyandgeneticbackgroundinacohortofpatientswithcvid